Patients with intracranial hemorrhage have to be managed aggressively to avoid or minimize secondary brain damage due to ischemia, which contributes to high morbidity and mortality. The risk of brain ischemia, however, is not the same in every patient. The risk of complications associated with an aggressive prophylactic therapy in patients with a low risk of brain ischemia can outweigh the benefits of therapy. Accurate and timely identification of patients at highest risk is a diagnostic challenge. Despite the availability of many diagnostic tools, stroke is common in this population, mostly because the pathogenesis of stroke is frequently multifactorial whereas diagnosticians tend to focus on one or two risk factors. The pathophysiological mechanisms of brain ischemia in patients with intracranial hemorrhage are not yet fully elucidated and there are several important areas of ongoing research. Therefore, this review describes physiological and pathophysiological aspects associated with the development of brain ischemia such as the mechanism of oxygen and carbon dioxide effects on the cerebrovascular system, neurovascular coupling and respiratory and cardiovascular factors influencing cerebral hemodynamics. Consequently, we review investigations of cerebral blood flow disturbances relevant to various hemodynamic states associated with high intracranial pressure, cerebral embolism, and cerebral vasospasm along with current treatment options.
ItoHKannoIKatoC. Database of normal human cerebral blood flow, cerebral blood volume, cerebral oxygen extraction fraction and cerebral metabolic rate of oxygen measured by positron emission tomography with 150-labelled carbon dioxide or water, carbon monoxide and oxygen: a Multicentre study in Japan. Eur J Nucl Med Mol Imaging.2004: 31: 635–643.
2.
HeleniusJPerkioJSoinneL. Cerebral hemodynamics in a healthy population measured by dynamic susceptibility contrast MR imaging. Acta Radiol.2003; 44: 538–546.
3.
ChihCPRobertsELJr. Energy substrates for neurons during neural activity: a Critical review of the astrocyte-neuron lactate shuttle hypothesis. J Cereb Blood Flow Metab.2003; 23: 1263–1281.
4.
BaskurtOKMeiselmanHJ. Blood rheology and hemodynamics. Semin Thromb Hemost.2003; 29: 435–450.
5.
McDonaldDA. Arterial impedance. In: McDonaldDA ed. Blood flow in arteries. Baltimore: Williams & Wilkins Co; 1977. p. 351–389.
6.
McDonaldDA. The numerical analysis of circulatory wave-forms. In: McDonaldDA ed. Blood flow in arteries. Baltimore: Williams & Wilkins Co; 1974. p. 146–173.
7.
LassenNA. Cerebral blood flow and oxygen consumption in man. Physiol Rev.1959; 39: 183–238.
8.
StrandgaardSOlesenJSkinhojE. Autoregulation of brain circulation in severe arterial hypertension. Br Med J.1973; 1: 507–510.
9.
WaldemarGSchmidtJFAndersenAR. Angiotensin converting enzyme inhibition and cerebral blood flow autoregulation in normotensive and hypertensive man. J Hypertens.1989; 7: 229–235.
10.
WallisSJFirthJDunnWR. Pressure-induced myogenic responses in human isolated cerebral resistance arteries. Stroke.1996; 27: 2287–2290; discussion 2291.
11.
Garcia-RoldanJLBevanJA. Flow-induced constriction and dilation of cerebral resistance arteries. Circ Res.1990; 66: 1445–1448.
12.
Thorin-TrescasesNBevanJA. High levels of myogenic tone antagonize the dilator response to flow of small rabbit cerebral arteries. Stroke.1998; 29: 1194–1200; discussion 1200–1191.
13.
McDonaldDA. Blood flow in arteries. Baltimore: Williams & Willkins Co; 1977.
14.
SlishDFWelshDCBraydenJE. Diacylglycerol and protein kinase C activate cation channels involved in myogenic tone. Am J Physiol Heart Circ Physiol.2002; 283: H2196–2201.
15.
KitamuraKXiongZTeramotoN. Roles of inositol trisphosphate and protein kinase C in the spontaneous outward current modulated by calcium release in rabbit portal vein. Pflugers Arch.1992: 421: 539–551.
16.
McCarronJGCrichtonCALangtonPD. Myogenic contraction by modulation of voltage-dependent calcium currents in isolated rat cerebral arteries. J Physiol.1997; 498 (Pt 2): 371–379.
17.
NgaiACWinnHR. Modulation of cerebral arteriolar diameter by intraluminal flow and pressure. Circ Res.1995; 77: 832–840.
18.
FaraciFM. Role of nitric oxide in regulation of basilar artery tone in vivo. Am J Physiol.1990; 259: H1216–1221.
19.
LeeJEKwakJSuhCK. Dual effects of nitric oxide on the large conductance calcium-activated potassium channels of rat brain. J Biochem Mol Biol.2006; 39: 91–96.
20.
MiyaharaKKawamotoTSaseK. Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. Eur J Biochem.1994: 223: 719–726.
21.
KontosHARaperAJPattersonJL. Analysis of vasoactivity of local pH, PCO2 and bicarbonate on pial vessels. Stroke.1977; 8: 358–360.
22.
HoriuchiTDietrichHHHongoK. Role of endothelial nitric oxide and smooth muscle potassium channels in cerebral arteriolar dilation in response to acidosis. Stroke.2002; 33: 844–849.
23.
KovecsKKomjatiKMartonT. Hypercapnia stimulates prostaglandin E(2) but not prostaglandin I(2) release in endothelial cells cultured from micro-vessels of human fetal brain. Brain Res Bull.2001: 54: 387–390.
24.
LindauerUVogtJSchuh-HoferS. Cerebrovascular vasodilation to extraluminal acidosis occurs via combined activation of ATP-sensitive and Ca2+-activated potassium channels. J Cereb Blood Flow Metab.2003; 23: 1227–1238.
25.
TodaNHatanoYMoriK. Mechanisms underlying response to hypercapnia and bicarbonate of isolated dog cerebral arteries. Am J Physiol.1989; 257: H141–146.
26.
SimpsonREPhillisJW. Adenosine deaminase reduces hypoxic and hypercapnic dilatation of rat pial arterioles: Evidence for mediation by adenosine. Brain Res.1991; 553: 305–308.
27.
FredricksKTLiuYRuschNJ. Role of endothelium and arterial K+ channels in mediating hypoxic dilation of middle cerebral arteries. Am J Physiol.1994; 267: H580–586.
28.
HoriuchiTDietrichHHHongoK. Mechanism of extracellular K+-induced local and conducted responses in cerebral penetrating arterioles. Stroke.2002; 33: 2692–2699.
29.
Di TullioMATayebatiSKAmentaF. Identification of adenosine A1 and A3 receptor subtypes in rat pial and intracerebral arteries. Neurosci Lett.2004; 366: 48–52.
30.
KleppischTNelsonMT. Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A2 receptors and cAMP-dependent protein kinase. Proc Natl Acad Sci USA.1995; 92: 12441–12445.
31.
LiGCheungDW. Modulation of Ca(2+)-dependent K(+) currents in mesenteric arterial smooth muscle cells by adenosine. Eur J Pharmacol.2000; 394: 35–40.
32.
BleysRLCowenT. Innervation of cerebral blood vessels: Morphology, plasticity, age-related, and Alzheimer's disease-related neurodegeneration. Microsc Res Tech.2001; 53: 106–118.
33.
BaffiJGorcsTSlowikF. Neuropeptides in the human superior cervical ganglion. Brain Res.1992: 570: 272–278.
34.
BaumbachGLHeistadDD. Effects of sympathetic stimulation and changes in arterial pressure on segmental resistance of cerebral vessels in rabbits and cats. Circ Res.1983; 52: 527–533.
35.
GoadsbyPJUddmanREdvinssonL. Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves. Brain Res.1996; 707: 110–118.
36.
HaraHHamillGSJacobowitzDM. Origin of cholinergic nerves to the rat major cerebral arteries: Coexistence with vasoactive intestinal polypeptide. Brain Res Bull.1985; 14: 179–188.
37.
Morita-TsuzukiYHardeboJEBouskelaE. Inhibition of nitric oxide synthase attenuates the cerebral blood flow response to stimulation of postganglionic parasympathetic nerves in the rat. J Cereb Blood Flow Metab.1993; 13: 993–997.
38.
EdvinssonLEkmanRJansenI. Calcitonin gene-related peptide and cerebral blood vessels: Distribution and vasomotor effects. J Cereb Blood Flow Metab.1987; 7: 720–728.
39.
EdvinssonLBrodinEJansenI. Neurokinin A in cerebral vessels: Characterization, localization and effects in vitro. Regul Pept.1988; 20: 181–197.
40.
EdvinssonLJansen OlesenIKingmanTA. Modification of vasoconstrictor responses in cerebral blood vessels by lesioning of the trigeminal nerve: Possible involvement of CGRP. Cephalalgia.1995; 15: 373–383.
41.
LassenLHHaderslevPAJacobsenVB. CGRP may play a causative role in migraine. Cephalalgia.2002; 22: 54–61.
42.
WeberJRAngstwurmKBoveCM. The trigeminal nerve and augmentation of regional cerebral blood flow during experimental bacterial meningitis. J Cereb Blood Flow Metab.1996; 16: 1319–1324.
43.
KalariaRNStockmeierCAHarikSI. Brain micro-vessels are innervated by locus ceruleus noradrenergic neurons. Neurosci Lett.1989; 97: 203–208.
44.
MorenoMJLopez de PabloACondeMV. Cat cerebral arteries are functionally innervated by serotoninergic fibers from central and peripheral origins. Stroke.1995; 26: 271–275; discussion 275–276.
45.
SatoASatoYUchidaS. Activation of the intracerebral cholinergic nerve fibers originating in the basal forebrain increases regional cerebral blood flow in the rat's cortex and hippocampus. Neurosci Lett.2004; 361: 90–93.
46.
CauliBTongXKRancillacA. Cortical GABA interneurons in neurovascular coupling: Relays for subcortical vasoactive pathways. J Neurosci.2004: 24: 8940–8949.
47.
MulliganSJ and MacVicarBA. Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. Nature.2004; 431: 195–199.
48.
WhiteRPHindleyCBloomfieldPM. The effect of the nitric oxide synthase inhibitor L-NMMA on basal CBF and vasoneuronal coupling in man: a Pet study. J Cereb Blood Flow Metab.1999; 19: 673–678.
49.
BelliveauJWKennedyDNJrMcKinstryRC, Functional mapping of the human visual cortexby magnetic resonance imaging. Science.1991; 254: 716–719.
50.
ZontaMAnguloMCGobboS. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci.2003; 6: 43–50.
BhardwajANorthingtonFJCarhuapomaJR. P-450 epoxygenase and NO synthase inhibitors reduce cerebral blood flow response to N-methyl-D-aspartate. Am J Physiol Heart Circ Physiol.2000: 279: H1616–1624.
53.
GebremedhinDLangeARLowryTF. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res.2000; 87: 60–65.
54.
ChristophersonKSHillierBJLimWA. PSD–95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem.1999; 274: 27467–27473.
55.
PelligrinoDAGayRL3rdBaughmanVL. NO synthase inhibition modulates NMDA-induced changes in cerebral blood flow and EEG activity. Am J Physiol.1996; 271: H990–995.
56.
Alonso-GaliciaMDrummondHAReddyKK. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension.1997; 29: 320–325.
57.
SunCWFalckJROkamotoH. Role of cGMP versus 20-HETE in the vasodilator response to nitric oxide in rat cerebral arteries. Am J Physiol Heart Circ Physiol.2000; 279: H339–350.
58.
KaraTNarkiewiczKSomersVK. Chemoreflexes–physiology and clinical implications. Acta Physiol Scand.2003; 177: 377–384.
59.
HeistadDDMarcusMLEhrhardtJC. Effect of stimulation of carotid chemoreceptors on total and regional cerebral blood flow. Circ Res.1976; 38: 20–25.
60.
MitchellRA. Respiratory chemosensitivity in the medulla oblongata. J Physiol.1969; 202: 3P–4P.
61.
JordanJShannonJRDiedrichA. Interaction of carbon dioxide and sympathetic nervous system activity in the regulation of cerebral perfusion in humans. Hypertension.2000; 36: 383–388.
62.
RoattaSMicieliGBosoneD. Effect of generalised sympathetic activation by cold pressor test on cerebral haemodynamics in healthy humans. J Auton Nerv Syst.1998; 71: 159–166.
63.
HeistadDDMarcusML. Total and regional cerebral blood flow during stimulation of carotid baroreceptors. Stroke.1976; 7: 239–243.
64.
RapelaCEGreenHDDenisonABJr. Baroreceptor reflexes and autoregulation of cerebral blood flow in the dog. Circ Res.1967; 21: 559–568.
65.
BondarRLKassamMSSteinF. Simultaneous cerebrovascular and cardiovascular responses during presyncope. Stroke.1995; 26: 1794–1800.
66.
MokriB. The Monro-Kellie hypothesis: Applications in CSF volume depletion. Neurology.2001; 56: 1746–1748.
KingmanTAMendelowADGrahamDI. Experimental intracerebral mass: Time-related effects on local cerebral blood flow. J Neurosurg.1987; 67: 732–738.
69.
SahayKBMehrotraRSachdevaU. Elastomechanical characterization of brain tissues. J Biomech.1992; 25: 319–326.
70.
JohnstonIHRowanJO. Raised intracranial pressure and cerebral blood flow. 3. Venous outflow tract pressures and vascular resistances in experimental intracranial hypertension. J Neurol Neurosurg Psychiatry.1974; 37: 392–402.
71.
IkeyamaAMaedaSItoA. The analysis of the intracranial pressure by the concept of the driving pressure from the vascular system. Neurochirurgia (Stuttg).1978; 21: 43–53.
72.
SwierczMMariakZKrejzaJ. Intracranial pressure processing with artificial neural networks: Prediction of ICP trends. Acta Neurochir (Wien).2000; 142: 401–406.
73.
MariakZSwierczMKrejzaJ. Intracranial pressure processing with artificial neural networks: Classification of signal properties. Acta Neurochir (Wien).2000; 142: 407–411; discussion 411–402.
74.
UngersbockKTenckhoffDHeimannA. Transcranial Doppler and cortical microcirculation at increased intracranial pressure and during the Cushing response: An experimental study on rabbits. Neurosurgery.1995; 36: 147–156; discussion 156–147.
75.
LinnFHRinkelGJAlgraA. Incidence of subarachnoid hemorrhage: role of region, year, and rate of computed tomography: a Meta-analysis. Stroke.1996: 27: 625–629.
76.
RothwellPMCoullAJGilesMF. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet.2004; 363: 1925–1933.
77.
ZachariaBEHickmanZLGrobelnyBT. Epidemiology of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am.2010; 21: 221–233.
78.
StapfCLabovitzDLSciaccaRR. Incidence of adult brain arteriovenous malformation hemorrhage in a prospective population-based stroke survey. Cerebrovasc Dis.2002; 13: 43–46.
79.
Martin-SchildSAlbrightKCHalleviH. Intracerebral hemorrhage in cocaine users. Stroke.2010; 41: 680–684.
80.
FaulMXuLWaldMM. Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths, 2002–2006. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.
81.
HaleyECJrKassellNFTornerJC. The International cooperative study on the timing of aneurysm surgery. The North American experience. Stroke.1992; 23: 205–214.
82.
HaleyECJrKassellNFApperson-HansenC. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a Cooperative study in North America. J Neurosurg.1997; 86: 467–474.
83.
ClaassenJBernardiniGLKreiterK. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: The Fisher scale revisited. Stroke.2001; 32: 2012–2020.
84.
HarrodCGBendokBRBatjerHH. Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a Review. Neurosurgery.2005; 56: 633–654; discussion 633–654.
85.
LongstrethWTJrNelsonLMKoepsellTD. Clinical course of spontaneous subarachnoid hemorrhage: a Population-based study in King County. Washington. Neurology.1993; 43: 712–718.
86.
SolenskiNJHaleyECJrKassellNF. Medical complications of aneurysmal subarachnoid hemorrhage: a Report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med.1995; 23: 1007–1017.
87.
HirashimaYKurimotoMTakabaM. The use of computed tomography in the prediction of delayed cerebral infarction following acute aneurysm surgery for subarachnoid haemorrhage. Acta Neurochir (Wien).1995; 132: 9–13.
88.
KivisaariRPSalonenOServoA. MR imaging after aneurysmal subarachnoid hemorrhage and surgery: a Long-term follow-up study. Am J Neuroradiol.2001; 22: 1143–1148.
89.
DreierJPSakowitzOWHarderA. Focal laminar cortical MR signal abnormalities after subarachnoid hemorrhage. Ann Neurol.2002; 52: 825–829.
90.
JuvelaSSiironenJVarisJ. Risk factors for ischemic lesions following aneurysmal subarachnoid hemorrhage. J Neurosurg.2005; 102: 194–201.
91.
EchlinFA. Vasospasm and focal cerebral ischemia: An experimental study. Arch Neurol Psychiatry.1942; 47: 77–96.
92.
RobertsonEG. Cerebral lesions due to intracranial aneurysms. Brain.1949; 72: 150–185.
93.
EckerARiemenschneiderPA. Arteriographic demonstration of spasm of the intracranial arteries, with special reference to saccular arterial aneurysms. J Neurosurg.1951; 8: 660–667.
94.
FalconerMA. Surgical pathology of spontaneous intracranial haemorrhage due to aneurysms and arteriovenousmalformations. Proc R Soc Med.1954; 47: 693–700.
95.
BirseSHTomMI. Incidence of cerebral infarction associated with ruptured intracranial aneurysms. A study of 8 unoperated cases of anterior cerebral aneurysm. Neurology.1960; 10: 101–106.
96.
CromptonMR. The Pathogenesis of cerebral infarction following the rupture of cerebral berry aneurysms. Brain.1964; 87: 491–510.
97.
SchneckSA. On the relationship between ruptured intracranial aneurysm and cerebral infarction. Neurology.1964; 14: 691–702.
98.
MendelowAD. Pathophysiology of delayed ischaemic dysfunction after subarachnoid haemorrhage: Experimental and clinical data. Acta Neurochir Suppl (Wien).1988; 45: 7–10.
99.
FaraciFMHeistadDD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res.1990; 66: 8–17.
100.
AdamsHPJr. Prevention of brain ischemia after aneurysmal subarachnoid hemorrhage. Neurol Clin.1992; 10: 251–268.
101.
GeraudGTremouletMGuellA. The prognostic value of noninvasive CBF measurement in subarachnoid hemorrhage. Stroke.1984; 15: 301–305.
102.
OhkumaHManabeHTanakaM. Impact of cerebral microcirculatory changes on cerebral blood flow during cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke.2000; 31: 1621–1627.
103.
RabinsteinAAFriedmanJAWeigandSD. Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke.2004; 35: 1862–1866.
104.
MathewNTMeyerJS. Pathogenesis and natural history of transient global amnesia. Stroke.1974; 5: 303–311.
105.
PlutaRMAfsharJKThompsonBG. Increased cerebral blood flow but no reversal or prevention of vasospasm in response to L-arginine infusion after subarachnoid hemorrhage. J Neurosurg.2000; 92: 121–126.
106.
MinhasPSMenonDKSmielewskiP. Positron emission tomographic cerebral perfusion disturbances and transcranial Doppler findings among patients with neurological deterioration after subarachnoid hemorrhage. Neurosurgery.2003; 52: 1017–1022; discussion 1022–1014.
107.
Stoltenberg-DidingerGSchwarzK. Brain lesions secondary to subarachnoid hemorrhage due to ruptured aneurysms. In: Cervos-NavarroJ and FersztR ed. Stroke and Microcirculation. New York: Raven Press; 1987. p. 471–480.
108.
Stoltenberg-DidingerG. Neuropathology of subarachnoid hemorrhage. In: BedersonJB ed. Subarachnoid hemorrhage: pathophysiology and management. Park Ridge, IL: American Association of Neurological Surgeons; 1997. p. 41–60.
LjunggrenBSavelandHBrandtL. Causes of unfavorable outcome after early aneurysm operation. Neurosurgery.1983; 13: 629–633.
111.
KassellNFTornerJCHaleyECJr. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J Neurosurg.1990; 73: 18–36.
112.
RabinsteinAAPichelmannMAFriedmanJA. Symptomatic vasospasm and outcomes following aneurysmal subarachnoid hemorrhage: a Comparison between surgical repair and endovascular coil occlusion. J Neurosurg.2003; 98: 319–325.
113.
HohBLCurryWTJrCarterBS. Computed tomographic demonstrated infarcts after surgical and endovascular treatment of aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien).2004; 146: 1177–1183.
114.
TreggiariMMWalderBSuterPM. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg.2003; 98: 978–984.
115.
KasuyaHOndaHTakeshitaM. Efficacy and safety of nicardipine prolonged-release implants for preventing vasospasm in humans. Stroke.2002; 33: 1011–1015.
116.
ZubkovAYLewisAIScalzoD. Transluminal angioplasty and intra-arterial papaverine for the treatment of cerebral vasospasm after ruptured arteriovenous malformations. Surg Neurol.1999; 51: 75–79; discussion 80.
117.
PolinRSCoenenVAHansenCA. Efficacy of transluminal angioplasty for the management of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg.2000: 92: 284–290.
118.
SteinSCCraccoRQ. Cortical injury without ischemia produced by topical monoamines. Stroke.1982; 13: 74–83.
119.
TasdemirogluEMacfarlaneRWeiEP. Pial vessel caliber and cerebral blood flow become dissociated during ischemia-reperfusion in cats. Am J Physiol.1992; 263: H533–536.
120.
PerkinsEKimuraHParentAD. Evaluation of the microvasculature and cerebral ischemia after experimental subarachnoid hemorrhage in dogs. J Neurosurg.2002; 97: 896–904.
121.
DietrichHHDaceyRGJr. Molecular keys to the problems of cerebral vasospasm. Neurosurgery.2000: 46: 517–530.
PrunellGFMathiesenTDiemerNH. Experimental subarachnoid hemorrhage: Subarachnoid blood volume, mortality rate, neuronal death, cerebral blood flow, and perfusion pressure in three different rat models. Neurosurgery.2003; 52: 165–175; discussion 175–166.
124.
PrunellGFSvendgaardNAAlkassK. Inflammation in the brain after experimental subarachnoid hemorrhage. Neurosurgery.2005; 56: 1082–1092; discussion 1082–1092.
125.
DreierJPEbertNPrillerJ. Products of hemolysis in the subarachnoid space inducing spreading ischemia in the cortex and focal necrosis in rats: a Model for delayed ischemic neurological deficits after subarachnoid hemorrhage?J Neurosurg.2000; 93: 658–666.
126.
BouchardBAShatosMATracyPB. Human brain pericytes differentially regulate expression of procoagulant enzyme complexes comprising the extrinsic pathway of blood coagulation. Arterioscler Thromb Vasc Biol.1997; 17: 1–9.
127.
RappJHPanXMYuB. Cerebral ischemia and infarction from atheroemboli <100 microm in Size. Stroke.2003; 34: 1976–1980.
128.
AtochinDNMurcianoJCGursoy-OzdemirY. Mouse model of microembolic stroke and reperfusion. Stroke.2004; 35: 2177–2182.
129.
HoshiTShimizuTKitoK. [Immunological study of late cerebral vasospasm in subarachnoid hemorrhage. Detection of immunoglobulins, C3, and fibrinogen in cerebral arterial walls by immunofluorescence method]. Neurol Med Chir (Tokyo).1984: 24: 647–654.
130.
PetersonJWKwunBDHackettJD. The role of inflammation in experimental cerebral vasospasm. J Neurosurg.1990; 72: 767–774.
131.
DumontASDumontRJChowMM. Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. Neurosurgery.2003; 53: 123–133; discussion 133–125.
132.
AiharaYKasuyaHOndaH. Quantitative analysis of gene expressions related to inflammation in canine spastic artery after subarachnoid hemorrhage. Stroke.2001; 32: 212–217.
133.
VingeEBrandtLLjunggrenB. Thromboxane B2 levels in serum during continuous administration of nimodipine to patients with aneurysmal subarachnoid hemorrhage. Stroke.1988; 19: 644–647.
134.
JuvelaSKasteMHillbomM. Platelet thromboxane release after subarachnoid hemorrhage and surgery. Stroke.1990; 21: 566–571.
135.
HirashimaYNakamuraSEndoS. Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res.1997; 22: 1249–1255.
136.
OsukaKSuzukiYTanazawaT. Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien).1998; 140: 943–951.
137.
GruberARosslerKGraningerW. Ventricular cerebrospinal fluid and serum concentrations of sTNFR-I, IL-1ra, and IL-6 after aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol.2000; 12: 297–306.
138.
ZhangZNagataIKikuchiH. Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: Vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB. Stroke.2001; 32: 1665–1672.
139.
KimDESuhYSLeeMS. Vascular NAD(P) H oxidase triggers delayed cerebral vasospasm after subarachnoid hemorrhage in rats. Stroke.2002; 33: 2687–2691.
140.
BorelCOMcKeeAParraA. Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. Stroke.2003; 34: 427–433.
141.
HendrykSJarzabBJoskoJ. Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett.2004; 25: 141–147.
142.
PolinRSBavbekMShaffreyME. Detection of soluble E-selectin, ICAM-1, VCAM-1, and L-selectin in the cerebrospinal fluid of patients after subarachnoid hemorrhage. J Neurosurg.1998; 89: 559–567.
143.
FassbenderKHodappBRossolS. Endothelin-1 in subarachnoid hemorrhage: An acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke.2000; 31: 2971–2975.
144.
NissenJJMantleDGregsonB. Serum concentration of adhesion molecules in patients with delayed ischaemic neurological deficit after aneurysmal subarachnoid haemorrhage: The immunoglobulin and selectin superfamilies. J Neurol Neurosurg Psychiatry.2001; 71: 329–333.
145.
MoriTNagataKTownT. Intracisternal increase of superoxide anion production in a canine subarachnoid hemorrhage model. Stroke.2001; 32: 636–642.
146.
NgWHMoochhalaSYeoTT. Nitric oxide and subarachnoid hemorrhage: Elevated level in cerebrospinal fluid and their implications. Neurosurgery.2001; 49: 622–626; discussion 626–627.
147.
SakowitzOWWolfrumSSarrafzadehAS. Temporal profiles of extracellular nitric oxide metabolites following aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl.2002; 81: 351–354.
Oliveira-FilhoJEzzeddineMASegalAZ. Fever in subarachnoid hemorrhage: Relationship to vasospasm and outcome. Neurology.2001; 56: 1299–1304.
150.
HughesJTSchianchiPM. Cerebral artery spasm. A histological study at necropsy of the blood vessels in cases of subarachnoid hemorrhage. J Neurosurg.1978; 48: 515–525.
151.
IulianoBAPlutaRMJungC. Endothelial dysfunction in a primate model of cerebral vasospasm. J Neurosurg.2004; 100: 287–294.
152.
SmithRRClowerBRGrotendorstGM. Arterial wall changes in early human vasospasm. Neurosurgery.1985; 16: 171–176.
153.
ZubkovAYTibbsREAokiK. Morphological changes of cerebral penetrating arteries in a canine double hemorrhage model. Surg Neurol.2000; 54: 212–219; discussion 219–220.
DocziT. The pathogenetic and prognostic significance of blood-brain barrier damage at the acute stage of aneurysmal subarachnoid haemorrhage. Clinical and experimental studies. Acta Neurochir (Wien).1985: 77: 110–132.
158.
DocziTJooFAdamG. Blood-brain barrier damage during the acute stage of subarachnoid hemorrhage, as exemplified by a new animal model. Neurosurgery.1986; 18: 733–739.
159.
SehbaFAMostafaGKnopmanJ. Acute alterations in microvascular basal lamina after subarachnoid hemorrhage. J Neurosurg.2004; 101: 633–640.
160.
ClowerBRYoshiokaJHonmaT. Blood platelets and early intimal changes in cerebral arteries following experimental subarachnoid hemorrhage. In: WilkinsRL ed. Cerebral vasospasm. New York: Raven Press; 1988. p. 334–342.
GoodnightSHKenoyerGRapaportSI. Defibrination after brain-tissue destruction: A serious complication of head injury. N Engl J Med.1974: 290: 1043–1047.
163.
DrakeTAMorrisseyJHEdgingtonTS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol.1989; 134: 1087–1097.
164.
FleckRARaoLVRapaportSI. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res.1990; 59: 421–437.
165.
EddlestonMde la TorreJCOldstoneMB. Astrocytes are the primary source of tissue factor in the murine central nervous system. A role for astrocytes in cerebral hemostasis. J Clin Invest.1993; 92: 349–358.
166.
DaySMReeveJLPedersenB. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood.2005; 105: 192–198.
167.
ValletBWielE. Endothelial cell dysfunction and coagulation. Crit Care Med.2001; 29: S36–41.
SteinSCSmithDH. Coagulopathy in traumatic brain injury. Neurocrit Care.2004; 1: 479–488.
170.
EttingerMG. Coagulation abnormalities in subarachnoid hemorrhage. Stroke.1970; 1: 139–142.
171.
KasuyaHShimizuTOkadaT. Activation of the coagulation system in the subarachnoid space after subarachnoid haemorrhage: Serial measurement of fibrinopeptide A and bradykinin of cerebrospinal fluid and plasma in patients with subarachnoid haemorrhage. Acta Neurochir (Wien).1988; 91: 120–125.
ItoyamaYFujiokaSTakakiS. Significance of elevated thrombin-antithrombin III complex and plasmin-alpha 2-plasmin inhibitor complex in the acute stage of nontraumatic subarachnoid hemorrhage. Neurosurgery.1994; 35: 1055–1060.
174.
SuzukiMKudoAOtawaraY. Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurgery.1999; 44: 487–493; discussion 493–484.
175.
OhkumaHSuzukiSKimuraM. Role of platelet function in symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke.1991; 22: 854–859.
176.
TsementzisSAHonanWPNightingaleS. Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochir (Wien).1990; 103: 116–121.
177.
SuzukiMKudoAOtawaraY. Fibrinolytic activity in the CSF and blood following subarachnoid haemorrhage. Acta Neurochir (Wien).1997; 139: 1152–1154.
178.
AntovicJBakicMZivkovicM. Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: Does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?Scand J Clin Lab Invest.2002; 62: 195–199.
179.
DentonICRobertsonJTDugdaleM. An assessment of early platelet activity in experimental subarachnoid hemorrhage and middle cerebral artery thrombosis in the cat. Stroke.1971; 2: 268–272.
180.
HirashimaYHamadaHKurimotoM. Decrease in platelet count as an independent risk factor for symptomatic vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg.2005; 102: 882–887.
181.
FujiiYTakeuchiSSasakiO. Serial changes of hemostasis in aneurysmal subarachnoid hemorrhage with special reference to delayed ischemic neurological deficits. J Neurosurg.1997; 86: 594–602.
182.
PeltonenSJuvelaSKasteM. Hemostasis and fibrinolysis activation after subarachnoid hemorrhage. J Neurosurg.1997; 87: 207–214.
183.
IlveskeroSJuvelaSSiironenJ. D-dimer predicts outcome after aneurysmal subarachnoid hemorrhage: No effect of thromboprophylaxis on coagulation activity. Neurosurgery.2005; 57: 16–24; discussion 16–24.
TaniEYamagataSItoY. Intercellular granules and vesicles in prolonged cerebral vasospasm. J Neurosurg.1978; 48: 179–189.
186.
ParraAMcGirtMJShengH. Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: Methodological analysis. Neurol Res.2002; 24: 510–516.
187.
SuzukiSSuzukiMIwabuchiT. Role of multiple cerebral microthrombosis in symptomatic cerebral vasospasm: With a case report. Neurosurgery.1983; 13: 199–203.
188.
SuzukiSKimuraMSoumaM. Cerebral microthrombosis in symptomatic cerebral vasospasm–a quantitative histological study in autopsy cases. Neurol Med Chir (Tokyo).1990; 30: 309–316.
189.
KlotzschCNahserHCHenkesH. Detection of microemboli distal to cerebral aneurysms before and after therapeutic embolization. Am J Neuroradiol.1998; 19: 1315–1318.
190.
GillerCAGillerAMLandreneauF. Detection of emboli after surgery for intracerebral aneurysms. Neurosurgery.1998; 42: 490–493; discussion 493–494.
191.
RomanoJGFortezaAMConchaM. Detection of microemboli by transcranial Doppler ultrasonography in aneurysmal subarachnoid hemorrhage. Neurosurgery.2002; 50: 1026–1030; discussion 1030–1021.
192.
RordorfGKoroshetzWJCopenWA. Diffusion- and perfusion-weighted imaging in vasospasm after subarachnoid hemorrhage. Stroke.1999; 30: 599–605.
193.
KaufmanHHMattsonJC. Coagulopathy in head injury. In: BeckerDPPJ ed. Central nervous system trauma status report. Bethesda: National Institute of Neurological and Communicative Disorders and Stroke; 1985. p. 187–206.
194.
YanamotoHKikuchiHOkamotoS. Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospasm in rabbits. Neurosurgery.1992; 30: 351–356; discussion 356–357.
195.
YanamotoHKikuchiHOkamotoS. Effects of protease inhibitor and immunosuppressant on cerebral vasospasm after subarachnoid hemorrhage in rabbits. Surg Neurol.1994; 42: 382–387.
196.
JuvelaS. Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg.1995; 82: 945–952.
197.
NiemiTTanskanenPTaxellC. Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol.1999; 11: 188–194.
198.
ThaiQAOshiroEMTamargoRJ. Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers. Stroke.1999; 30: 140–147.
199.
PhilipponJGrobRDagreouF. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien).1986; 82: 110–114.
200.
SeilerRWGrolimundPZurbrueggHR. Evaluation of the calcium-antagonist nimodipine for the prevention of vasospasm after aneurysmal subarachnoid haemorrhage. A prospective transcranial Doppler ultrasound study. Acta Neurochir (Wien).1987; 85: 7–16.
201.
RoosYBLeviMCarrollTA. Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage. Stroke.2001; 32: 1860–1862.
202.
NishidaKMarkeySP. Nicardipine and MK-801 attenuate platelet-activating factor increases following cerebral ischemia-reperfusion in gerbils. Brain Res.1996; 733: 203–210.
203.
ParraAKreiterKTWilliamsS. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a Matched controlled cohort study. Neurosurgery.2005; 56: 476–484; discussion 476–484.
204.
EndresMLaufsU. Effects of statins on endothelium and signaling mechanisms. Stroke.2004; 35: 2708–2711.
205.
LuDMahmoodAGoussevA. Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. J Neurosurg.2004; 101: 813–821.
206.
LuDGoussevAChenJ. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma.2004; 21: 21–32.
207.
TokiyoshiKOhnishiTNiiY. Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. Surg Neurol.1991; 36: 112–118.
208.
AbeYKasuyaHSuzukiS. Effect of a platelet-activating factor antagonist, E5880, on cerebrovasospasm following subarachnoid hemorrhage in a canine double-hemorrhage model. Eur J Pharmacol.2002: 455: 127–133.
209.
ChowMDumontASKassellNF. Endothelin receptor antagonists and cerebral vasospasm: An update. Neurosurgery.2002; 51: 1333–1341; discussion 1342.
210.
LeviMKellerTTvan GorpE. Infection and inflammation and the coagulation system. Cardiovasc Res.2003; 60: 26–39.
211.
LeviMten CateHvan der PollT. Endothelium: Interface between coagulation and inflammation. Crit Care Med.2002; 30: S220–224.
212.
GandoSKameueTMatsudaN. Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma. Thromb Haemost.2002; 88: 943–949.
213.
AsadaMKongJNakamuraM. Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: Its efficacy and problems. Neurol Res.1996; 18: 342–344.
214.
HamadaJKaiYMoriokaM. Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cisterna magna: a Prospective randomized study. Stroke.2003; 34: 2549–2554.
RordorfGBellonRJBudzikREJr. Silent thromboembolic events associated with the treatment of unruptured cerebral aneurysms by use of Guglielmi detachable coils: Prospective study applying diffusion-weighted imaging. Am J Neuroradiol.2001; 22: 5–10.
217.
SoedaASakaiNSakaiH. Thromboembolic events associated with Guglielmi detachable coil embolization of asymptomatic cerebral aneurysms: Evaluation of 66 consecutive cases with use of diffusion-weighted MR imaging. Am J Neuroradiol.2003; 24: 127–132.
218.
AlbayramSSelcukD. Thromboembolic events associated with Guglielmi detachable coil embolization of asymptomatic cerebral aneurysms: Evaluation of 66 consecutive cases with use of diffusion-weighted MR imaging. Am J Neuroradiol.2004; 25: 159–160; author reply 160.
219.
SoedaASakaiNMuraoK. Thromboembolic events associated with Guglielmi detachable coil embolization with use of diffusion-weighted MR imaging. Part II. Detection of the microemboli proximal to cerebral aneurysm. Am J Neuroradiol.2003; 24: 2035–2038.
220.
DorschNWKingMT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: Incidence and effects. J Clin Neurosci.1994; 1: 19–26.
221.
KassellNFSasakiTColohanAR. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke.1985; 16: 562–572.
222.
WeirBGraceMHansenJ. Time course of vasospasm in man. J Neurosurg.1978; 48: 173–178.
223.
van GijnJKerrRSRinkelGJ. Subarachnoid haemorrhage. Lancet.2007; 369: 306–318.
224.
JaegerMSchuhmannMUSoehleM. Continuous monitoring of cerebrovascular autoregulation after subarachnoid hemorrhage by brain tissue oxygen pressure reactivity and its relation to delayed cerebral infarction. Stroke.2007; 38: 981–986.
225.
VergouwenMDVermeulenMCoertBA. Microthrombosis after aneurysmal subarachnoid hemorrhage: An additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab.2008; 28: 1761–1770.
226.
KosnikEJHuntWE. Postoperative hypertension in the management of patients with intracranial arterial aneurysms. J Neurosurg.1976; 45: 148–154.
227.
SenJBelliAAlbonH. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage. Lancet Neurol.2003; 2: 614–621.
DankbaarJWSlooterAJRinkelGJ. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a Systematic review. Crit Care.2010; 14: R23.
230.
van GijnJRinkelGJ. Subarachnoid haemorrhage: Diagnosis, causes and management. Brain.2001; 124: 249–278.
231.
ShimodaMOdaSTsuganeR. Intracranial complications of hypervolemic therapy in patients with a delayed ischemic deficit attributed to vasospasm. J Neurosurg.1993; 78: 423–429.
SteinerTJuvelaSUnterbergA. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis.2013; 35: 93–112.
234.
ConnollyESJrRabinsteinAACarhuapomaJR. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a Guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke.2012; 43: 1711–1737.
235.
VergouwenMDMeijersJCGeskusRB. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a Double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab.2009; 29: 1444–1453.
236.
VergouwenMDde HaanRJVermeulenM. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a Systematic review and meta-analysis update. Stroke.2010; 41: e47–52.
237.
Dorhout MeesSMAlgraAVandertopWP. Magnesium for aneurysmal subarachnoid haemorrhage (MASH–2): a Randomised placebo-controlled trial. Lancet.2012; 380: 44–49.
238.
RabinsteinAAWeigandSAtkinsonJL. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke.2005; 36: 992–997.
239.
SchmidtJMWartenbergKEFernandezA. Frequency and clinical impact of asymptomatic cerebral infarction due to vasospasm after subarachnoid hemorrhage. J Neurosurg.2008; 109: 1052–1059.
240.
ShimodaMTakeuchiMTominagaJ. Asymptomatic versus symptomatic infarcts from vasospasm in patients with subarachnoid hemorrhage: Serial magnetic resonance imaging. Neurosurgery.2001: 49: 1341–1348; discussion 1348–1350.
241.
MaybergMRBatjerHHDaceyR. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke.1994; 25: 2315–2328.
